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Abstract: The perception of pain caused by inflammation serves as a warning sign to avoid
further injury. The generation and transmission of pain impulses involves various pathways and
receptors. Cardamonin isolated from Boesenbergia rotunda (L.) Mansf. has been reported to exert
antinociceptive effects in thermal and mechanical pain models; however, the precise mechanism
has yet to be examined. The present study investigated the possible mechanisms involved in the
antinociceptive activity of cardamonin on protein kinase C, N-methyl-d-aspartate (NMDA) and
non-NMDA glutamate receptors, l-arginine/cyclic guanosine monophosphate (cGMP) mechanism,
as well as the ATP-sensitive potassium (K+) channel. Cardamonin was administered to the animals
intra-peritoneally. Present findings showed that cardamonin significantly inhibited pain elicited by
intraplantar injection of phorbol 12-myristate 13-acetate (PMA, a protein kinase C activator) with
calculated mean ED50 of 2.0 mg/kg (0.9–4.5 mg/kg). The study presented that pre-treatment with
MK-801 (NMDA receptor antagonist) and NBQX (non-NMDA receptor antagonist) significantly
modulates the antinociceptive activity of cardamonin at 3 mg/kg when tested with glutamate-induced
paw licking test. Pre-treatment with l-arginine (a nitric oxide precursor), ODQ (selective inhibitor of
soluble guanylyl cyclase) and glibenclamide (ATP-sensitive K+ channel inhibitor) significantly
enhanced the antinociception produced by cardamonin. In conclusion, the present findings
showed that the antinociceptive activity of cardamonin might involve the modulation of PKC
activity, NMDA and non-NMDA glutamate receptors, l-arginine/nitric oxide/cGMP pathway and
ATP-sensitive K+ channel.
Keywords: cardamonin; glutamate receptor; l-arginine nitric oxide pathway; cGMP; potassium
channels; acute pain
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1. Introduction
Cardamonin, a natural occurring chalcone, which is chemically known as 2′,4′-dihydroxy-6′-
methoxychalcone (C16H14O4), was initially isolated from the seeds of Amomum subulatum [1]. To date,
cardamonin isolated from Alpinia rafflesiana, Alpinia henryi, Alpinia katsumadai, and Campomanesia
adamantium has been extensively studied. Cardamonin was reported to exert anti-inflammatory
properties [2,3], vasorelaxation of rat mesenteric artery [4], anti-proliferative activity and induced
apoptosis [5–7], protection against acute lung injury in septic mice [8], anti-mutagenic effects [9],
improved insulin resistance in high fructose-fed rat model [10], pigmentation inhibitory effect in
normal human melanocytes [11], inhibition against pruritis [12], nephroprotective effect against
cisplatin-induced renal injury [13], and inhibition of the differentiation of preadipocytes into
adipocytes [14]. Cardamonin showed promising effects in a number of cancer studies, involving colon,
breast, ovarian and gastric cancer cell lines [15–22]. In vivo study of cardamonin treatment against
rheumatoid arthritis presented inhibition on inflammation as well as pain through behavioural,
biochemical and histological studies; plasma evaluation of the treated animals also showed promising
inhibition in pro-inflammatory cytokine levels [23]. Therapeutic effect of cardamonin on chronic
constriction injury-induced neuropathic pain has been reported through a series of thermal and
mechanical pain studies [24].
Both in vitro and ex vivo studies reported that cardamonin possessed inhibitory action against
pro-inflammatory cytokine production [2,25]. Further studies reported the inhibitory action of
cardamonin against inflammatory responses involved in the disruption of nitric oxide (NO) production
and the downregulation of the iNOS expression via modulation of the NF-ҡB pathway [3,25,26].
An in vivo study with lipopolysaccharide (LPS)-challenged ICR mice model reported that cardamonin
also suppressed the generation of nitric oxide [27]. A previous study presented that cardamonin showed
antinociceptive activity against PBQ-induced writhing and carrageenan-indyced hyperalgesia [28,29].
Taking all these into account, a deeper understanding of the mechanism of antinociceptive activity
of cardamonin has to be carried out. In a previous study, cardamonin demonstrated antinociceptive
activity through a acetic acid-induced abdominal writing test, hot plate test and glutamate-induced
nociception tests [29]. Activation of N-methyl-d-aspartate (NMDA) and non-NMDA glutamate
receptors is probably involved in the glutamate-induced nociception. In particular, activation of
NMDA receptor is mediated by the l-arginine-nitric oxide-cyclic GMP pathway [30,31]. Thus, in the
present study, we attempted to study the possible participation of ionotropic glultamate receptors and
nitric oxide/cyclic GM/ATP-sensitive K+ channel pathway in the antinociceptive activity of cardamonin.
2. Results
2.1. Antinociceptive Analysis
2.1.1. Acetic Acid-Induced Abdominal Writhing Test
The result in Figure 1 presented the effect of systemically administered cardamonin in acetic
acid-induced abdominal writhing test. Cardamonin at the dose of 0.3, 1, 3 and 10 mg/kg produced
significant dose-dependent inhibition against acetic acid-induced pain, with the percentage of inhibition
at 45%, 56%, 80% and 100%, respectively. For the use throughout the experiments in the mechanism
studies, the calculated mean ED50 value for intraperitoneal administration of cardamonin was 2.1 mg/kg
(1.9–2.5 mg/kg). Indomethacin (Indo; 10 mg/kg; i.p.), which served as the positive control drug, showed
significant inhibition, with 80% of inhibition against acetic acid-induced pain in mice, according to our
previously published results [29].
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Figure 1. Effect of cardamonin (0.3, 1, 3 and 10 mg/kg; i.p.) against acetic acid-induced nociception.
Each column represents the mean ± S.E.M. of six mice. Control group received only the vehicle (ethanol:
Tween 20: distilled water in 5:5:90, v/v) used to dilute the compound. Indomethacin (Indo; 10 mg/kg;
i.p.) was used as positive control. Statistical analysis was determined by one-way ANOVA, followed by
Tukey’s post hoc test. Values with different superscript letters are statistically different from each other
at p < 0.05.
2.1.2. Involvement of Protein Kinase C
The intraperitoneal administration of cardamonin at doses of 0.3, 1, 3 and 10 mg/kg demonstrated
significant dose dependent inhibition in phorbol 12-myristate 13-acetate (PMA)-induced paw licking
test in mice, with 61%, 68%, 74% and 83% of inhibition respectively (Figure 2). The calculated mean
ED50 value for this study was 2.0 mg/kg (CI, 0.9–4.5 mg/kg). Indomethacin (Indo; 10 mg/kg; i.p.) was
used as the positive control drug and it showed significant inhibition as compared to the control group,
with 81% of inhibition against PMA-induced nociception.
Figure 2. Effect of cardamonin (0.3, 1, 3 and 10 mg/kg; i.p.) against phorbol 12-myristate 13-acetate
(PMA)-induced nociception. Each column represents the mean ± S.E.M. of 6 mice. Control group
receives only the vehicle used to dilute the compound. Indomethacin (Indo; 10 mg/kg; i.p.) was used
as the positive control drug. Statistical analysis was determined by one-way ANOVA, followed by
Tukey’s post hoc test. Values with different superscript letters are statistically different from each other
at p < 0.05.
2.1.3. Effect of MK-801 and NBQX on Glutamate-Induced Nociception
Figure 3 presented the antinociceptive effect of cardamonin on NMDA glutamate receptor subtype
(Panel A) and non-NMDA glutamate receptor subtype (Panel B) when assessed in glutamate-induced
paw licking test. NMDA receptor antagonist, MK-801 (0.3 mg/kg; i.p.) produced significant inhibition
when administered alone intraperitoneally, with 86% of inhibition in paw licking when compared to the
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control group. Pre-treatment with MK-801 prior to the administration of cardamonin (1 and 3 mg/kg)
significantly enhanced the effect of the cardamonin treatment alone respectively. Administration
of AMPA/kainate receptor antagonist, NBQX (3 mg/kg; i.p.) alone produced significant inhibition
in glutamate-induced nociception, with 48% of inhibition when compared to the control group.
Pre-treatment with NBQX produced no significant changes for the treatment with cardamonin 1 mg/kg
when compared to the treatment alone, but when treated with cardamonin 3 mg/kg, NBQX significantly
reversed the antinociceptive effect of cardamonin.
All Figures 3–6 are misaligned as indicated by yellow highlights. Please check attached original
manuscript file.
Figure 3. Effect of MK-801 (0.3 mg/kg; i.p.) (panel A) and NBQX (3 mg/kg; i.p.) (panel B) on
antinociception caused by cardamonin (1 and 3 mg/kg; i.p.) in glutamate-induced paw licking test.
Each column represents the mean ± S.E.M. of 6 mice. Statistical analysis was determined by one-way
ANOVA, followed by Tukey’s post hoc test. Values with different superscript letters are statistically
different from each other at p < 0.05.
2.2. Analysis of the Possible Mechanism of Action of Cardamonin
2.2.1. Involvement of l-arginine/Nitric Oxide Pathway
The result depicted in Figure 4 showed that pre-treatment with nitric oxide precursor, l-arginine
(100 mg/kg; i.p.), at a dose that produced no significant different as compared to the control group,
significantly reversed the antinociception exhibited by the nitric oxide synthase inhibitor, l-NOARG
(20 mg/kg; i.p.) and significantly enhanced the antinociceptive effect of cardamonin (1 mg/kg; i.p.),
when analysed with an acetic acid-induced nociceptive test.
Molecules 2020, 25, 5385 5 of 15
Figure 4. Effect of pre-treatment with l-arginine (100 mg/kg; i.p.) on antinociceptive activity of
cardamonin (1 mg/kg; i.p.) and l-NOARG (20 mg/kg; i.p.) against acetic acid-induced abdominal
writhing test in mice. Each column represents the mean ± S.E.M. of six mice. Statistical analysis was
determined by one-way ANOVA, followed by Tukey’s post hoc test. Values with different superscript
letters are statistically different from each other at p < 0.05.
2.2.2. Involvement of Cyclic Guanosine Monophosphate (cGMP)
The result depicted in Figure 5 showed the effect of cardamonin upon the injection of the specific
guanylyl cyclise inhibitor, ODQ (2 mg/kg; i.p.) and analysed with acetic acid-induced nociceptive
test. Both ODQ and cardamonin, when administered alone, produced significant inhibition in acetic
acid-induced abdominal writhing test. However, when given together, ODQ significantly enhanced
the antinociceptive effect of cardamonin compared to the treatment alone.
Figure 5. Effect of ODQ (2 mg/kg; i.p.) pre-treatment on antinociceptive activity of cardamonin
(1 mg/kg; i.p.) against acetic acid-induced abdominal writhing test in mice. Each column represents
the mean ± S.E.M. of six mice. Statistical analysis was determined by one-way ANOVA, followed by
Tukey’s post hoc test. Values with different superscript letters are statistically different from each other
at p < 0.05.
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2.2.3. Involvement of ATP-Sensitive K+ Channel
The pre-treatment with ATP-sensitive K+ channel inhibitor, glibenclamide (10 mg/kg; i.p.),
produced no significant difference as compared with the control group when administered alone,
but significantly enhanced the antinociceptive effect of cardamonin (1 mg/kg; i.p.) in the acetic
acid-induced abdominal writhing test (Figure 6).
Figure 6. Effect of glibenclamide (10 mg/kg; i.p.) pre-treatment on antinociceptive activity of cardamonin
(1 mg/kg; i.p.) against acetic acid-induced pain in mice. Each column represents the mean ± S.E.M. of
six mice. Statistical analysis was determined by one-way ANOVA, followed by Tukey’s post hoc test.
Values with different superscript letters are statistically different from each other at p < 0.05.
3. Discussion
The perception of pain involves various pathways which transmit the pain impulses from the site
of injury to the peripheral nervous system then central nervous system. A previous study showed
that cardamonin exhibited antinociceptive action by interrupting the opioidergic pathway and TRPA1
activation [24,32]. Cardamonin was reported to inhibit nociception through action on TRPV1 channel
and glutamate receptors [29]. The stimulation of nerve endings involves the release of various
inflammatory mediators which lead to sensitization of respective receptors embedded on the neurons
surface [33].
Prostaglandin E2 sensitization of TRPV1 activity in mice involves protein kinase C (PKC)-
dependent pathway [34]. The findings of the present study shows that the antinociceptive effect
of cardamonin involved inhibition of protein kinase C activity. The systemic administration of
cardamonin exhibited significant dose dependent inhibition against overt nociception induced by
phorbol-12-myristate-13-acetate (PMA)-induced paw licking test. The protein kinase C signalling
pathway plays an important role in regulating the excitation of sensory neurons through the
phosphorylation of membrane-bound receptors and ion channels. The injection of PMA, a phorbol
ester which represent pharmacological analogues of diacylglycerol, into the mouse paw through
intraplantar injection, directly activates protein kinase C [35]. The nociceptive behavioural responses
induced by the injection of PMA into mouse paw attributed to translocation of protein kinase C
isoforms from cytoplasmic region to peripheral ending of primary afferent nerves [35,36]. Thus, it was
postulated that cardamonin might inhibit the translocation of protein kinase C to the primary afferent
nerve endings, which then reduced peripheral nociception. Previous study reported that activation of
protein kinase C potentiates the effect of capsaicin on TRPV1 receptor [37]. Protein kinase C mediated
sensitization of TRPV1 receptor enhances glutamatergic synaptic transmission at the central terminal
of sensory neurons in the dorsal horn of spinal cord [38]. At the central level, cardamonin might have
the capability to interfere with the binding of protein kinase C to TRPV1 receptor and thus reduces
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the influx of calcium, as well as decreases glutamate activity, resulting in inhibition upon paw licking
behavioural responses.
Cardamonin has been reported to exert inhibition of pain behaviour against glutamate-induced
nociceptive test in mice [29]. There are three subtypes of ionotropic glutamate receptors, namely α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-d-aspartate (NMDA)
glutamate receptors. The AMPA receptors are thought to mediate rapid excitatory neurotransmission
in the central nervous system in the earlier findings, but recent studies have demonstrated that spinal
AMPA receptors contribute in the development of both acute and painful responses. The C-terminal
intracellular regulatory domain of AMPA receptor subunit presents multiple phosphorylation sites for
various protein kinases participate in the regulation of AMPA receptor function. The activation of
protein kinase cascades, including calcium/calmodulin protein kinase II (CaMKII), protein kinase C
(PKC) and protein kinase A (PKA) by noxious stimulation in the periphery tissues, may play a crucial
role in the phosphorylation of glutamate receptors in spinal nociceptive neurons, which then followed
by enhanced activity of glutamatergic synapses [39].
In the present study, animals were treated with quinoxalinedione antagonist, NBQX to block out
glutamate binding to the non-NMDA receptors, but this antagonist has a limitation in distinguishing
AMPA from kainate receptors [40]. The present findings suggest that cardamonin at the dose of 3 mg/kg
exerted its antinociceptive property, possibly by blocking the binding of glutamate to AMPA receptor
and inhibition of protein kinase cascades, in particular, protein kinase C-mediated phosphorylation of
glutamate receptors, which then lead to reduced activity at glutamatergic synapses.
The activation of NMDA glutamate receptor in chronic pain settings happens at peripheral, spinal and
supraspinal level of neural axis [41]. Peripheral administration of NMDA receptor antagonists attenuated
the nociceptive behaviours caused by local injections of glutamate or NMDA, which shows there is
the presence of NMDA receptors in the periphery [42]. The present study reported that systemic
injection of NMDA receptor antagonist could reduce the nociceptive behaviours caused by local injection
of glutamate into mouse paw; in which, intraperitoneal administration of MK-801 (NMDA receptor
antagonist) showed significant inhibition in glutamate-induced paw licking behaviour when compared to
the control group. Consistent with these findings, MK-801 also produced a dose dependent inhibition in
glutamate-induced nociception when administered at periphery, systemic, spinal and supraspinally [30].
Despite the antinociceptive property, NMDA receptor antagonists also caused disturbance in motor
coordination, but these two effects cannot be separated [30,43].
This study presented that cardamonin showed significant inhibition but not as effective as MK-801
when tested in glutamate-induced paw licking test. When pre-treated with MK-801, cardamonin was
able to produce significant enhancement of inhibitory effect when compared to their respective dose
treatment of cardamonin. These findings suggested that the inhibitory effect of cardamonin might
involve the blocking NMDA receptor. Thus, the present study postulated that the antinociceptive
effect of cardamonin in glutamate-induced nociception might involve the modulation of the activity of
ionotropic glutamate receptor, including NMDA, AMPA and kainate receptors.
Nitric oxide is a diffusible gas that functions as a neurotransmitter in the pain processing pathway.
The catalytic action performed by nitric oxide synthase (NOS), generates nitric oxide from l-arginine
and molecular oxygen [44]. The administration of l-arginine systemically into the peritoneal region
provided substrates for the action of the enzyme nitric oxide synthase (NOS) to produce a sufficient
amount of nitric oxide to induce pain-related behaviour when examined with acetic acid-induced
abdominal constriction model. Thus, in order to control the synthesis of nitric oxide, one must regulate
the activity of its producing enzyme, which is the nitric oxide synthase (NOS) [45].
Previous studies reported that the administration of nitric oxide synthase inhibitors, both systemically
and intrathecally, are capable to reduce hyperalgesia [46,47]. Furthermore, it was reported that
l-NG-nitro-arginine (l-NOARG), which is a selective inhibitor of nitric oxide biosynthesis,
showed antinociceptive activity when tested in a mouse model [48]. In the present study,
systemic administration of Nω-nitro-l-arginine (l-NOARG) has reduced the pain induced by acetic acid,
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as shown by the reduced abdominal constriction behaviour of the tested animals. Upon administration
of the selective inhibitor of nitric oxide synthase (NOS), l-NOARG inhibited the synthesis of nitric
oxide by inactivating the enzyme. Thus, disturbance in the downstream signalling by nitric oxide
that regulates various ion channels leads to the cessation of pain processing. On the other hand,
when l-arginine was administered prior to the selective inhibitor of nitric oxide synthase, l-NOARG,
the inhibitory effect of l-NOARG, was reversed as the nitric oxide produced sufficient enough to
induce pronociceptive behaviour.
In order to determine whether the antinociceptive pathway of cardamonin involves the inhibition of
nitric oxide signalling, the animals were pre-treated with l-arginine prior to the systemic administration
of cardamonin. The results showed that the group cardamonin pre-treated with l-arginine exhibited
significantly enhanced inhibition in acetic acid-induced pain behavioural study when compared with
the group treated with cardamonin only. Since cardamonin was postulated to block the NMDA receptor,
the influx of calcium ion into the intracellular cavity is reduced; thus, the calcium/calmodulin-dependent
nitric oxide synthase (NOS) fails to catalyse l-arginine into nitric oxide and l-citrulline, which then
leads to disruption of pain signalling. It was also suggested that downstream signalling of nitric oxide
pain signalling pathway involves the release of glutamate [49]. Thus, the present study suggested that
the enhanced antinociceptive effect of cardamonin when pre-treated with l-arginine probably involves
the modulation of the glutamate receptors.
The administration of ODQ, a selective inhibitor of soluble guanylyl cyclase, was expected to
reduce the synthesis of cGMP, and thus reduce the behavioural response against pain. In the group
of animals treated with ODQ prior to cardamonin, it produced enhanced antinociceptive activity
with a decrease in abdominal writhing response, as compared to the cardamonin only treated group.
This study postulated that the enhanced inhibitory effect may be attributed to the synergistic effect
of both ODQ and cardamonin. The soluble guanylyl cyclase inhibitor, ODQ should reduce the
synthesis of cGMP; the downstream signalling pathway may lead to pain processing; with additional
help from cardamonin that has shown its inhibitory effect against glutamate, nitric oxide and other
neurotransmitters, the inhibitory action in the nociceptive behavioural study has improved as compared
with their individual treatment respectively. Furthermore, it was reported that ODQ significantly
decreased the glutamate concentration and reduced the intensity of NMDA-induced pain-related
behaviour [49]. Thus, cardamonin was postulated to exert its antinociceptive activity by inhibiting the
NMDA activation evoked by nitric oxide/cGMP/glutamate release cascade.
The activation of nociceptors initiates an increase in inward currents by activating the
non-potassium channels and/or reduction in outward currents that leads to membrane depolarization,
followed by the generation of action potential. The membrane depolarization and excitation of dorsal
root ganglion neurons by nociceptive stimuli provide a basis for the manifestation of ATP-sensitive
potassium channel opening. The opening of potassium channels plays a pivotal role in regulating
resting membrane potential and action potential firing threshold [50,51].
Glibenclamide is one of the sulfonylurea drugs that bind to sulfonylurea receptor (SUR) protein
and affect the opening of ATP-sensitive potassium channels [52]. Previous studies reported that
sulfonylurea drugs, such as glibenclamide, cause neither hyperalgesia nor antinociceptive activity
when tested individually [53]. Furthermore, administration of glibenclamide alone did not affect the
pain behaviour that arises from formalin injection, at both phase 1 and phase 2 [54]. The results of this
study were in agreement with these evidences, in which glibenclamide, when injected alone, did not
caused any changes in pain behaviour when tested with acetic acid-induced abdominal writhing
test as compared to the control group. Pre-treatment of glibenclamide has blocked the opening of
ATP-sensitive potassium channels, but when treated with cardamonin, the pain behaviour induced by
acetic acid has greatly reduced and was significantly different from the group pre-treated with vehicle.
Nitric oxide plays dual effects on nociception and antinociception. The antinociceptive effects of
nitric oxide involves the activation of ATP-sensitive potassium channels [55]. Nitric oxide binding to the
soluble guanlyl cyclase (sGC) catalyzes guanosine triphosphate (GTP) forming 3′,5′-cyclic monophosphate
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(cGMP), followed by the activation of cGMP-dependent protein kinase (PKG). The ATP-sensitive potassium
channels phosphorylated by PKG leads to membrane potential hyperpolarization, thus resulting in
cessation of nociceptive signal transmission [56,57]. In addition, a study showed that nitric oxide
was capable of up-regulating the expression of ATP-sensitive potassium channel in primary sensory
neurons [58]. The findings in the present study suggested that cardamonin might facilitate in the
up-regulation of ATP-sensitive potassium channels expression in the presence of nitric oxide.
4. Methodology
4.1. Plant Material
The fresh rhizomes of Boesenbergia rotunda (5 kg) were commercially purchased from the local
market, Serdang, Malaysia, and were authenticated by a resident botanist at the Institute of Bioscience
(IBS), Universiti Putra Malaysia (UPM). A voucher specimen (SK1780/10) was deposited at the
Herbarium, which was located at Laboratory of Natural Products, IBS, UPM. A small part of the
rhizomes was cultivated in the Medicinal Plant Garden at IBS, UPM for future reference.
4.2. Extraction and Isolation
The fresh rhizomes of Boesenbergia rotunda were sliced into small flat pieces and dried under
shadow for one week. The dried rhizomes were ground into fine powder by using domestic food
processor. The dried powder 2.5 kg was dissolved in distilled methanol for two to three days.
The methanolic extract was filtered and concentrated on rotary evaporator and 255 g of crude extract
was obtained. The methanolic extract was subjected to solvent extraction. The crude methanolic
extract was dissolved in 250 mL distilled water and transferred into a separating funnel. About 150 mL
hexane was added into aqueous layer and subsequently extracted with chloroform, ethyl acetate and
butanol. The chloroform layer finally passed over sodium sulphate anhydrous to remove the moisture.
The chloroform extract was subjected to flash column chromatography by using ethyl acetate and
hexane as eluents. Finally, the compound was purified from chloroform extract and identified as
cardamonin after performing the detailed spectroscopic techniques [23,29].
4.3. Experimental Animals
Adult male ICR mice (20–30 g) were used throughout the study. Animals were randomly divided
into six mice per group (n = 6) and were housed at the Animal House of Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia. The condition of housing was set at 12 h light/12 h dark cycle
with free access to standard pellet and water ad libitum. Animals were acclimatized to the condition
of the laboratory one hour before the experiments. All of the animals were used only once in the
experiment. Handling of animals and experiments was conducted according to the Ethical Guidelines
for Investigation of Experimental Pain in Conscious Animals (Zimmermann, 1983) by the International
Association for the Study of Pain (IASP). This study has been approved by the Institutional Animal
Care and Use Committee (IACUC) UPM (Ref: UPM/FPSK/PADS/BR-UUH/00425).
4.4. Drugs and Chemicals
The following reagents and drugs were used: Tween 20, absolute ethanol, DMSO, indomethacin,
MK-801, NBQX, glutamate, l-arginine, Nω-nitro-l-arginine (l-NOARG), 1H-[1,2,4]Oxadiazolo[4,3-a]
quinoxalin-1-one (ODQ), phorbol 12-myristate 13-acetate (PMA), and glibenclamide. All the chemicals
and drugs mentioned were purchased from Sigma Chemical Co. (USA). All drugs were dissolved in
physiological saline (0.9% NaCl) unless otherwise mentioned. ODQ was dissolved in 5% DMSO and
PMA was dissolved in phosphate buffered saline (PBS). Cardamonin and indomethacin were dissolved in
ethanol, Tween 20 and distilled water in 5:5:90 (v/v) fractions. Respective controls received only solvent
vehicle, whereby it had no effect per se on nociceptive responses. All drugs and cardamonin solution were
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freshly prepared and administered intraperitoneally (i.p.) in a volume of 10 µ/kg, unless otherwise stated in
the method.
4.5. Antinociceptive Analysis
4.5.1. Acetic Acid-Induced Abdominal Writhing Test
The acetic acid-induced abdominal writhing test was carried out as previously described [59], with
slight modifications. Animals were pre-treated with cardamonin (0.3, 1, 3 and 10 mg/kg; i.p.), 30 min
before the challenge with injection of 0.8% acetic acid (10 mL/kg; i.p.). Doses of cardamonin used was
reported does not cause any apparent qualitative toxicity and disruption in motor coordination on
animals [29]. The control group received a similar volume of vehicle (10 mL/kg; i.p.). Indomethacin
(Indo, 10 mg/kg; i.p.) was used as the reference drug. Following the injection of acetic acid, the animals
were immediately placed into a Perspex chamber and the number of abdominal writhes was recorded
for 30 min, beginning 5 min after the acetic acid injection.
4.5.2. Involvement of Protein Kinase C
The experiment was carried out as previously described [60,61]. A volume of 20 µL of phorbol
12-myristate 13-acetate (PMA; 0.03 µg/paw) was injected intraplantarly (i.p.) into the ventral surface
of the right hind paw. Animals were individually placed into an observation chamber and were
observed from 15 to 45 min following PMA injection. The amount of time spent licking and biting the
injected paw was timed with a chronometer and was considered to be indicative of pain. The animals
were treated with cardamonin (0.3, 1, 3 and 10 mg/kg; i.p.), indomethacin (10 mg/kg; i.p.) or vehicle
(10 mg/kg; i.p.) 30 min before PMA injection.
4.5.3. Effect of MK-801 and NBQX on Glutamate-Induced Nociception
To investigate the possible participation of NMDA receptor in the antinociceptive effect of
cardamonin, the procedure used was similar to that previously described [30,62,63], with slight
modifications. The animals were pre-treated with MK-801 (0.3 mg/kg; i.p.; NMDA receptor antagonist)
or NBQX (3 mg/kg; i.p.; non-NMDA receptor antagonist) 15 min before injection of either vehicle
(10 mL/kg; i.p.) or cardamonin (1 and 3 mg/kg; i.p.). The animals were then challenged with the
injection of 20 µL of glutamate (10 µmol/paw) into the ventral surface of the right hind paw, 30 min
after the treatment. Animals were then observed individually for 15 min following glutamate injection.
The amount of time spent licking and biting the injected paw was timed with a chronometer and
considered as an indication of nociception.
4.6. Analysis of the Possible Mechanism of Action of Cardamonin
4.6.1. Involvement of l-arginine/Nitric Oxide Pathway
To assess the possible participation of the l-arginine/nitric oxide pathway in the antinociceptive
effect of cardamonin in acetic acid test, animals were pre-treated with l-arginine (100 mg/kg; i.p.; a nitric
oxide precursor), 15 min before the administration of cardamonin (1 mg/kg; i.p.), Nω-nitro-l-arginine
(l-NOARG; 20 mg/kg; i.p.; a nitric oxide synthase inhibitor) or vehicle (10 mL/kg; i.p.) as described
previously [64,65]. Nociceptive responses against acetic acid were then recorded for 30 min after
the administration of cardamonin, l-NOARG or vehicle, began 5 min after the acetic acid injection.
The numbers of abdominal writhing were considered as indication of pain behaviour. Another group
of animals were pre-treated with vehicle (10 mL/kg; i.p.), and after 15 min, they received cardamonin
(1 mg/kg; i.p.), l-NOARG (20 mg/kg; i.p.) or vehicle, 30 min before acetic acid injection.
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4.6.2. Involvement of Cyclic Guanosine Monophosphate (cGMP)
To elucidate the possible contribution of cGMP in the antinociceptive effect of cardamonin in
the acetic acid test, animals were pre-treated with ODQ (2 mg/kg; i.p.; a selective inhibitor of soluble
guanylyl cyclise), 15 min before the administration of cardamonin (1 mg/kg; i.p.) or vehicle (10 mL/kg;
i.p.) as described previously [66,67], with slight modifications. Nociceptive responses against acetic
acid were then recorded for 30 min after the administration of cardamonin or vehicle, beginning 5 min
after the acetic acid injection. The numbers of abdominal writhing were counted as indication of pain
behaviour. Another group of animals were pre-treated with vehicle (10 mL/kg; i.p.), and after 15 min,
they received cardamonin (1 mg/kg; i.p.) or vehicle, 30 min before acetic acid injection.
4.6.3. Involvement of ATP-Sensitive K+ Channel
In order to investigate the possible participation of K+ channel in the antinociceptive effect of
cardamonin in acetic acid test, animals were pre-treated with glibenclamide (10 mg/kg; i.p.; an ATP-sensitive
K+ channel inhibitor), 15 min prior to the injection of either cardamonin (1 mg/kg; i.p.) or vehicle (10 mL/kg;
i.p.), as described previously [60,64], with slight modifications. The animals were then challenged with
acetic acid (i.p.) 30 min after the treatment. The animals were immediately placed into a Perspex chamber
after injection of acetic acid and the numbers of abdominal writhing were recorded for 30 min, began
5 min after the acetic acid injection. Another group of animals were pre-treated with vehicle (10 mL/kg;
i.p.), and after 15 min, they received cardamonin or vehicle, 30 min before acetic acid injection.
4.7. Data Analysis
The data collected were expressed as mean ± S.E.M. for six animals per group and analysed using
one-way ANOVA followed by Tukey’s multiple comparison test. The differences between means
were considered as statistically significant at p < 0.05. The percentage of inhibition was calculated by
comparing the results of treatment group with control group.
5. Conclusions
Findings in the present study suggested that systemic administration of cardamonin, in doses
that does not produce any apparent toxicity and motor impairment in animals, exerted antinociceptive
effects through the inhibition of PKC activation, modulation of NMDA and non-NMDA glutamate
receptors, interruption of NMDA activation evoked nitric oxide/cGMP/glutamate release cascade,
and the modulation of nitric oxide/cGMP-mediated activation of ATP-sensitive potassium channels.
The precise mechanism underlying remains to be investigated through molecular analysis.
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